NCR3 and neoplasm: PGE2 inhibits NK cell effector receptors, such as NCR2/NKp44, NCR1/NKp46, NCR3/NKp30, NKG2D, and CD16 (Fig. 9) [243], leading to impaired function and promoting tumor immune evasion.